Ginkgo biloba extract (GbE) is a dietary supplement derived from an ethanolic extract of Ginkgo biloba leaves. Unfinished bulk GbE is used to make finished products that are sold as dietary supplements. The variable, complex composition of GbE makes it difficult to obtain consistent toxicological assessments of potential risk. The National Toxicology Program (NTP) observed hepatotoxicity in its rodent studies of a commercially available, unfinished GbE product, but the application of these results to the broader GbE supplement market is unclear. Here, we use a combination of non-targeted and targeted chromatographic and spectrophotometric methods to obtain profiles of 24 commercially available finished GbE products and unfinished standardized and unstandardized extracts with and without hydrolysis, then used principal component analysis to group unfinished products according to their similarity to each other and to National Institute of Standards and Technology (NIST) standard reference materials (SRM), and the finished products. Unfinished products were grouped into those that were characteristic and uncharacteristic of standardized GbE. Our work demonstrates that different analytical approaches produced similar classifications of characteristic and uncharacteristic products in unhydrolyzed samples, but the distinctions largely disappeared once the samples were hydrolyzed. Using our approach, the NTP GbE was most similar to two unfinished GbE products classified as characteristic, finished products, and the NIST GbE SRM. We propose that a simple analysis for the presence, absence, or amounts of compounds unique to GbE in unhydrolyzed samples could be sufficient to determine a sample’s authenticity.Graphical abstract
10 October 2016 in Environmental Science and Pollution Research
The analytical quality of compounds subjected to high-throughput screening (HTS) impacts accurate interpretation of assay results, with poor quality samples potentially leading to false negatives or positives. The Tox21 "10K" library consists of over 8900 unique compounds, spanning a diverse landscape of environmental and pharmaceutical chemicals, posing opportunities and challenges for analytical quality control (QC) determinations. Tox21 sample plates stored in DMSO at ambient conditions for 0 (T0) and/or 4 months (T4), totaling more than 13K unique sample identifiers (Tox21 IDs), were subjected to various analyses, including liquid and gas chromatography mass spectrometry (LC-MS, GC-MS) and nuclear magnetic resonance (NMR). Results for each sample at T0 or T4 underwent expert review and, where possible, a QC grade conveying purity, identity, and concentration was assigned. Herein, we relate details of the methods applied and report on the original (v0) Tox21 ID level results. Thirteen QC grades were condensed to 5 quality scores to aid global analysis, resulting in reinterpretation and improvement of >700 sample grades. Of the 92% T0 samples successfully graded, 76% exceeded 90% purity. For 76% of samples that were also tested at T4, 89% showed no evidence of sample loss or degradation. Prioritized quality bins were used to summarize thousands of replicate sample-level QC results to a compound-level QC score to support structure-based analyses. ToxPrint chemotype analysis identified structural features enriched in unstable compounds, as well as in high and low quality T0 subsets. Predicted vapor pressure was weakly correlated with low-concentration QC indicators, reflecting likely entanglement with method amenability and quality issues. Finally, an ongoing EPA effort to re-evaluate the original QC spectra is generating insights that will further modify QC grades. Tox21 QC spectra and results will be made available in a new public QC browser, facilitating further evaluation to support HTS interpretation and modeling applications.